Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Scientific Papers of Interest
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Scientific Papers of Interest
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2025 August
  • Home
  • Archive for August, 2025
Global Trial Podcast
user

Host: Julio Martinez linkedin-img

user

Guest: Ross Youngs linkedin-img


×

Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere

  • August 29 2025
  • Video - Date: 08/28/2025
  • Length: 29.44 min

Summary –

Discussed in this Podcast

→ How microbiome mining could cure cancer, Alzheimer’s & more
→ Processing 2 MILLION liters of water daily to extract microbes
→ Accessing drug-like molecules that evolution perfected over 3.4 billion years
→ Why this could be worth TRILLIONS in the next 25 years
→ Transforming agriculture, cosmetics & environmental remediation

lightbulbKEY TAKEAWAY: “Microbes have always been chemical researchers and factories of life. Biosortia’s breakthrough technology now effectively opens the door to ALL microbes.” – Ross Youngs

This technology could literally transform how we discover new medicines and accelerate first-in human trials globally!

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI

  • August 15 2025

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI (August 15, 2025) by Mariam E Sunny. Summary Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal’s lead candidate not part of deal with Lilly. Aug 14 (Reuters) – Eli Lilly (LLY.N), has signed a deal worth $1.3 billion with privately

Continue Reading

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

  • August 14 2025

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, and tiered royalties (August 14, 2025) by Sarah Sutton. Boston, MA — August 14, 2025

Continue Reading

RSS Industry News

  • A Muribaculaceae-enriched microbiota exacerbates TLR4-dependent Acinetobacter baumannii-induced hyperinflammatory sepsis April 30 2026
  • Navigating the translational labyrinth of the gut microbiota April 29 2026
  • Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial April 27 2026
  • Community context reshapes microbial proteomes and reduces functional overlap April 24 2026
  • Author Correction: Commensal yeast promotes Salmonella Typhimurium virulence April 24 2026
  • The network structure of cross-feeding impacts microbial community diversity under growth-inhibiting stresses April 23 2026
  • Ketogenic diet exacerbates DSS-induced colitis through a β-hydroxybutyrate-Thomasclavelia spiroformis-γδ17 T cell axis in mice April 23 2026
  • Human milk oligosaccharide mediates mutualism between Escherichia coli and Bifidobacterium bifidum April 22 2026
  • A pro-carcinogenic bacterial toxin binds claudin-4 to cleave E-cadherin April 22 2026
  • Gut microorganisms turn low-protein diet into fat browning April 22 2026
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • Polypeptides synthesized by common bacteria in the human gut improve rodent metabolism
  • Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound
  • Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2026. All Rights Reserved.